AMRX · Amneal Pharmaceuticals
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $19.10
Note written ·
Price against the kill line
11.9% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $19.10, on record since 10 November 2026; only a weekly close settles it. The shares are up 16.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $19.10, the prior high the shares cleared in September 2026, which would return them to their pre-breakout range. A cut to the 3 November 2026 guidance of $3.15–3.25 billion revenue or $800–815 million adjusted EBITDA would also break the case.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 863
- Revenue, change on a year (%)
- +10.0
- Gross margin (%)
- 38.7
- Operating margin (%)
- 11.1
- Free cash flow, four quarters ($M)
- 88.2
- Net cash, cash less debt ($M)
- −2,782
- Price to earnings (×)
- 55.9
- Enterprise value to sales (×)
- 3.2
All filed numbers
What Amneal Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 863 | +10.0 | 38.7 | 11.1 |
| first filed | 796 | +9.9 | 42.0 | 16.3 |
| first filed | 723 | +3.9 | 44.3 | 19.6 |
| first filed | 814 | +11.5 | 36.5 | 13.8 |
| first filed | 785 | +11.7 | 34.9 | 9.0 |
| first filed | 725 | +3.2 | 39.5 | 15.4 |
| Pre-tax income ($M) | 15.1 |
| Net income ($M) four quarters: 133 | −21.7 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +3.4 |
| Operating cash flow ($M) | 181 |
| Capital spending ($M) | 92.4 |
| Free cash flow ($M) | 88.2 |
| Cash and short-term investments ($M) | 157 |
| Debt ($M) long-term debt | 2,939 |
| Net cash, cash less debt ($M) | −2,782 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | 708 |
| Shareholders' equity ($M) | 531 |
| Market value ($M) | 7,449 |
| Enterprise value, market value plus net debt ($M) | 10,231 |
| Enterprise value to sales (×) | 3.2 |
| Enterprise value to operating income (×) | 21.4 |
| Price to earnings (×) | 55.9 |
| Price to book value (×) | 14.0 |
| Free-cash-flow yield (%) | 1.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 4.0% of shares outstanding sold short, 3.7 days of average trading to cover, +24.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $8.3M |
The thesis
Amneal Pharmaceuticals is more likely than not to beat the S&P 500 over the next three months. Its shift toward biosimilars (lower-cost copies of biologic drugs), specialty drugs and complex generics is showing in reported results, and the report expected around late February 2027 settles whether the lanreotide launch ramps and net debt falls as management promised.
Amneal guides to 2026 revenue of $3.15–3.25 billion and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $800–815 million, per its 3 November 2026 results release. Third-quarter revenue of $863 million beat estimates, and the 10-Q filed on 9 November 2026 confirms $862.68 million against $784.51 million a year earlier.
The shares closed at $21.70 on 12 November 2026, up from $18.15 on 14 August 2026, and 1.7% below the intraday 52-week high of $22.07 set that day. UBS's target of $28 and the $25 targets from JPMorgan and Leerink sit above that close, so brokers still see room above the current price.
Bullish and bearish views on Amneal Pharmaceuticals, Inc.
The bull case on Amneal Pharmaceuticals, Inc. (AMRX), in brief: results beat and guidance rose. The bear case: debt rose with the Kashiv deal.
Bull case
- Results beat and guidance rose. Third-quarter revenue was $863 million, up 10% from a year earlier, and adjusted EBITDA was $207 million, up 30%, per the 3 November 2026 release. Adjusted earnings per share (EPS) was $0.26, up from $0.17.
- Both growth segments accelerated. Affordable Medicines revenue rose 19% to $547 million on biosimilars, women's health patches and new launches. Specialty rose 20% to $150 million, per the same release, after 17% growth in the second quarter.
- Lanreotide starts small with room to grow. The chief financial officer put the third-quarter contribution at about $7 million and expects the fourth quarter to be "multiple times of that," per a transcript of the 3 November 2026 call. Management targets 30–40% market share over time.
- Kashiv removes profit sharing. Management cited $400–500 million of expected benefits from ending profit-sharing obligations and said Amneal now keeps all lanreotide profit, per the 3 November 2026 call. It also outlined a 2030 revenue target of $4.3–4.5 billion.
- Broker targets moved higher after the report. UBS raised its target to $28 from $25 on 6 November 2026, per market reports. JPMorgan (Overweight) went to $25 from $24 on 4 November 2026, per MarketBeat, and Leerink (Outperform) to $25 on 5 November 2026.
Bear case
- Debt rose with the Kashiv deal. Gross debt was $3,231 million and net leverage 3.9 times at 30 September 2026, up from 3.5 times at the end of 2025, per the release. Management expects to end 2026 at 3.6 times.
- Cash flow guidance fell as earnings guidance rose. The 2026 operating cash flow range dropped to $325–375 million from $350–400 million, per the release. Management attributed the change to an inventory build and collections moving into the first quarter of 2027.
- The Xolair biosimilar moved later. Management said on 3 November 2026 that the U.S. omalizumab biosimilar has a goal date in early 2027, with launch expected late in the second half of 2027 under a patent settlement not yet struck.
- AvKARE is shrinking. The AvKARE distribution segment fell 17% to $165 million in the third quarter, per the 3 November 2026 release, offsetting part of the growth elsewhere.
- Registered shares can come to market. The 3 September 2026 Form S-3ASR registers 28,942,098 Class A shares held by Kashiv sellers for resale, and Amneal receives nothing from any sale. Insider Form 4 filings since late August show gifts of shares by Executive Vice President Andrew Boyer and a director's option exercise at $14.45 on 11 September 2026, with no open-market sales listed.
Price setup
The shares closed at $20.14 on 6 November 2026 and at $21.28 on 9 November 2026, the first session after the 10-Q filing and the UBS raise. They then closed at $21.38 on 10 November 2026, $21.71 on 11 November 2026 and $21.70 on 12 November 2026. The 52-week high is $22.07 on 12 November 2026.
The three-month change is 19.6%. The last close sits above the 50-day average of $19.64 and the 200-day average of $16.06, both from adjusted daily closes as of 12 November 2026. The 52-week closing low was $11.52 on 20 November 2025.
The shares have moved above the September 2026 prior high they cleared before the report. A weekly close back under that level would return them to their pre-breakout range and undo the post-report gains.
Catalysts ahead
- ~30 November 2026 (est.): Expected final European approval of the Kashiv-developed omalizumab biosimilar, handled outside the U.S. by partners Alvotech and Advanz. Tests regulatory progress on Amneal's largest near-term biosimilar ahead of the U.S. decision.
- ~15 February 2027 (est.): U.S. goal date for the omalizumab biosimilar, described by management only as early 2027. Approval, along with any patent settlement, would fix when the Xolair biosimilar can contribute, now expected late in the second half of 2027.
- ~26 February 2027 (est.): Fourth-quarter and full-year 2026 results, date not yet announced. Shows the lanreotide ramp, year-end net leverage against the 3.6 times target, cash flow against the lowered range and the first 2027 guidance.
What would change the view
A weekly close below $19.10, the prior high the shares cleared in September 2026, which would return them to their pre-breakout range. A cut to the 3 November 2026 guidance of $3.15–3.25 billion revenue or $800–815 million adjusted EBITDA would also break the case.
The risks this note tracks, each with what would confirm it:
- Lanreotide ramps more slowly than management's fourth-quarter comment implies. Confirmed by: the next report shows fourth-quarter lanreotide revenue that is not a clear multiple of the roughly $7 million reported for the third quarter.
- Debt reduction after the Kashiv deal falls behind plan. Confirmed by: year-end 2026 net leverage above management's 3.6 times, or a retreat from the goal of under three times by 2028.
- The cash flow shortfall proves more than timing. Confirmed by: a further cut to the $325–375 million 2026 operating cash flow range, or collections that fail to arrive in the first quarter of 2027.
- The U.S. omalizumab biosimilar slips again. Confirmed by: a complete response letter from the Food and Drug Administration, or a patent settlement dating launch beyond 2027.
- Resale of registered Kashiv shares adds supply to the market. Confirmed by: Form 144 or Form 4 filings showing sales by Kashiv holders, or a prospectus supplement naming a sale.
What it trades with
Amneal trades as a U.S. generic and specialty drugmaker with a large debt load, so it tends to move with interest-rate expectations and with generic peers such as Teva and Viatris more than with large-cap pharma. Drug-pricing policy headlines and tariff news on imported pharmaceuticals hit the group together. Company-specific moves follow its own quarterly reports and Food and Drug Administration decisions on biosimilars and complex generics.
The evidence, claim by claim (8)
- Third-quarter 2026 net revenue was $863 million, up 10% from $785 million a year earlier; adjusted EBITDA was $207 million, up 30%; adjusted diluted EPS was $0.26, up from $0.17. The GAAP net loss was $22 million. Amneal Q3 2026 results release, Form 8-K exhibit 99.1 · as of
- Affordable Medicines revenue rose 19% to $547 million, Specialty rose 20% to $150 million and AvKARE fell 17% to $165 million. Amneal Q3 2026 results release, Form 8-K exhibit 99.1 · as of
- 2026 guidance rose to revenue of $3.15–3.25 billion, adjusted EBITDA of $800–815 million and adjusted EPS of $1.04–1.08, from $3.10–3.20 billion, $750–780 million and $0.96–1.06. Amneal Q3 2026 results release, Form 8-K exhibit 99.1 · as of
- 2026 operating cash flow guidance fell to $325–375 million from $350–400 million, which the company attributed to working capital including higher inventory. Amneal Q3 2026 results release, Form 8-K exhibit 99.1 · as of
- Gross debt was $3,231 million, net debt $3,073 million and net leverage 3.9 times, against 3.5 times at the end of 2025. Amneal Q3 2026 results release, Form 8-K exhibit 99.1 · as of
- Lanreotide contributed about $7 million in the third quarter; management expects the fourth quarter to be multiple times that and targets 30–40% market share over time. Amneal Q3 2026 earnings call transcript · as of
- UBS raised its Amneal price target to $28 from $25; JPMorgan moved to $25 from $24 on 4 November 2026 and Leerink to $25 on 5 November 2026. Analyst rating reports via rallies.ai and MarketBeat · as of
- Quarterly revenue of $862.68 million against $784.51 million a year earlier, for the period ended 30 September 2026. Form 10-Q filed 9 November 2026 (SEC XBRL) · as of
Sources